Laurus Labs Ltd

LAURUSLABS

Company Profile

  • Business description

    Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.

  • Contact

    Road No. 7, Banjara Hills
    2nd Floor, Serene Chambers
    HyderabadTG500034
    IND

    T: +91 4039804333

    https://www.lauruslabs.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 March 2026

    Employees

    12,467

Stocks News & Analysis

stocks

Procter & Gamble earnings: Frigid sales and margins don’t suggest cracks in its standing

North America was a notable blemish, down 2% on an organic basis.
stocks

Our view on Santos after production is ramped up

Barossa at 75% capacity and Pikka undergoing commissioning.
stocks

GE Aerospace earnings: No good deed goes unpunished

We’ve raised our fair value estimate of GE Aerospace stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,189.9015.700.17%
CAC 408,128.3220.57-0.25%
DAX 4024,882.4025.930.10%
Dow JONES (US)49,384.01306.780.63%
FTSE 10010,160.8810.830.11%
HKSE26,749.51119.550.45%
NASDAQ23,436.02211.200.91%
Nikkei 22553,846.87157.980.29%
NZX 50 Index13,448.24108.63-0.80%
S&P 5006,913.3537.730.55%
S&P/ASX 2008,860.1015.000.17%
SSE Composite Index4,136.1613.590.33%

Market Movers